Aprea Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Aprea reported $41.2M cash (June 30, 2026) vs. $14.6M (Dec 31, 2025), reflecting a $30M private placement closed in Q1 2026. Lead program APR-1051 (WEE1 inhibitor) in Phase 1 ACESOT-1051 trial showed preliminary activity: 2 partial responses and 6 stable disease cases across 28 patients as of May 6, 2026 cutoff; enrollment accelerating from 3 to 10 sites with target of 6–10 patients/month by Q4 2026. Q2 2026 net loss was $3.6M ($0.07/share on 53.5M shares) vs. $3.2M ($0.53/share on 6.1M shares) in Q2 2025. Company projects cash runway into Q1 2028.
Why this rating
Early clinical proof-of-concept in lead asset meaningful for 8.6M market-cap biotech; $30M raise extended runway substantially; q4 2026 data catalyst; however, Phase 1 responses in 28 patients remain preliminary and unconfirmed.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.